Insphero

InSphero AG develops organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell-invasion assays, stem-cell research, cell-to-cell interaction, regenerative medicine, tissue engineering, and cell-to-extracellular matrix interaction services. In addition, it involves in study of transcriptomics, proteomics, and metabolomics. Further, the company provides custom development services, which include microtissue development, H and E stained paraffin sections, growth characteristics data, and morphometric data. Its microtissue system enables the generation of various model systems using either tumor-derived cells to reconstitute primary tumors or primary cells to mimic structure and function of diverse organ tissues. InSphero AG was founded in 2009 and is based in Zurich, Switzerland.

show less